Analyst Ratings for [MRNA] Moderna, Inc.

3/13/25	Initiated	Neutral	X
MRNA Moderna Citigroup
$40
2/18/25	Downgrades	Overweight Eq Weight	X
MRNA Moderna Barclays
$111 $45
1/29/25	Downgrades	Buy Neutral	X
MRNA Moderna Goldman
$99 $51
12/10/24	Resumed	Underperform	X
MRNA Moderna BofA Securities
$41
11/19/24	Initiated	Hold	X
MRNA Moderna Berenberg
$42
11/18/24	Upgrades	Hold Buy	X
MRNA Moderna HSBC Securities
$58
11/15/24	Initiated	Underperform	X
MRNA Moderna Wolfe Research
$40
10/17/24	Initiated	Mkt Perform	X
MRNA Moderna Bernstein
$55
9/13/24	Downgrades	Buy Hold	X
MRNA Moderna Jefferies
$120 $65
9/13/24	Downgrades	Neutral Underweight	X
MRNA Moderna JP Morgan
$88 $70
9/13/24	Downgrades	Outperform Perform	X
MRNA Moderna Oppenheimer
8/28/24	Upgrades	Reduce Hold	X
MRNA Moderna HSBC Securities
$82
8/7/24	Upgrades	Sell Hold	X
MRNA Moderna Deutsche Bank
$85 $80
8/5/24	Downgrades	Outperform Sec Perform	X
MRNA Moderna RBC Capital Mkts
$125 $90
2/26/24	Downgrades	Hold Reduce	X
MRNA Moderna HSBC Securities
$75 $86
1/2/24	Upgrades	Perform Outperform	X
MRNA Moderna Oppenheimer
$142
11/29/23	Initiated	Hold	X
MRNA Moderna Canaccord Genuity
$82
11/3/23	Upgrades	Reduce Hold	X
MRNA Moderna HSBC Securities
$89 $69
11/2/23	Downgrades	Hold Sell	X
MRNA Moderna Deutsche Bank
$125 $60
8/4/23	Downgrades	Outperform Mkt Perform	X
MRNA Moderna TD Cowen
$145 $125
8/3/23	Downgrades	Buy Hold	X
MRNA Moderna Deutsche Bank
$125
7/24/23	Initiated	Mkt Perform	X
MRNA Moderna William Blair
$136.28
7/14/23	Initiated	Reduce	X
MRNA Moderna HSBC Securities
$97
6/26/23	Upgrades	Neutral Buy	X
MRNA Moderna UBS
$221 $191
4/26/23	Initiated	Neutral	X
MRNA Moderna Guggenheim
3/13/23	Upgrades	Mkt Perform Outperform	X
MRNA Moderna TD Cowen
$150 $180
3/2/23	Initiated	Outperform	X
MRNA Moderna RBC Capital Mkts
$200
2/24/23	Downgrades	Mkt Perform Underperform	X
MRNA Moderna SVB Securities
$111 $93
12/19/22	Upgrades	Hold Buy	X
MRNA Moderna Jefferies
$170 $275
12/14/22	Downgrades	Buy Neutral	X
MRNA Moderna Chardan Capital Markets
$186 $191
10/21/22	Upgrades	Underperform Mkt Perform	X
MRNA Moderna SVB Leerink
$174 $101
9/8/22	Upgrades	Hold Buy	X
MRNA Moderna Deutsche Bank
$165
2/1/22	Upgrades	Sell Neutral	X
MRNA Moderna Redburn
1/26/22	Upgrades	Sell Hold	X
MRNA Moderna Deutsche Bank
$175
1/21/22	Upgrades	Underperform Neutral	X
MRNA Moderna BofA Securities
$135 $180
1/21/22	Initiated	Neutral	X
MRNA Moderna UBS
$221
12/7/21	Initiated	Market Perform	X
MRNA Moderna Cowen
11/9/21	Initiated	Outperform	X
MRNA Moderna Wolfe Research
$304
10/22/21	Initiated	Sell	X
MRNA Moderna Deutsche Bank
$250
10/15/21	Upgrades	Neutral Overweight	X
MRNA Moderna Piper Sandler
$445
7/15/21	Reiterated	Hold	X
MRNA Moderna Jefferies
$170 $250
2/1/21	Downgrades	Neutral Underperform	X
MRNA Moderna BofA Securities
4/5/19	Initiated	Buy	X
MRNA Moderna Chardan Capital Markets
$40
1/2/19	Initiated	Overweight	X
MRNA Moderna Barclays
$20
1/2/19	Initiated	Buy	X
MRNA Moderna BofA/Merrill
$20
1/2/19	Initiated	Buy	X
MRNA Moderna Goldman
$25
1/2/19	Initiated	Overweight	X
MRNA Moderna JP Morgan
$22
1/2/19	Initiated	Overweight	X
MRNA Moderna Morgan Stanley
$29
1/2/19	Initiated	Buy	X
MRNA Moderna Needham
$28
1/2/19	Initiated	Overweight	X
MRNA Moderna Piper Jaffray
$24

MRNA Moderna, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Moderna, Inc. develops medicines based on messenger RNA (mRNA). Its pipeline includes development candidates for mRNA-based vaccines and therapies for use in various therapeutic areas comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.